{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T23:42:17Z","timestamp":1766533337591,"version":"3.48.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"DOI":"10.7759\/cureus.99956","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T23:39:49Z","timestamp":1766533189000},"source":"Crossref","is-referenced-by-count":0,"title":["Treatment of Fibroblast Growth Factor-23-Mediated Renal Phosphate Wasting With Burosumab in a Patient With Chronic Kidney Disease 3b: A Case Report"],"prefix":"10.7759","author":[{"given":"Christopher H","family":"Goss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geethika","family":"Earthineni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishwajeeth","family":"Pasham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tibor","family":"F\u00fcl\u00f6p","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2023.101851","article-title":"The pathophysiology of hypophosphatemia","volume":"38","author":"Ito N","year":"2024","unstructured":"Ito N, Hidaka N, Kato H. The pathophysiology of hypophosphatemia. Best Pract Res Clin Endocrinol Metab. 2024, 38:101851. 10.1016\/j.beem.2023.101851","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-020-00691-6","article-title":"Tumor-induced osteomalacia","volume":"108","author":"Florenzano P","year":"2021","unstructured":"Florenzano P, Hartley IR, Jimenez M, Roszko K, Gafni RI, Collins MT. Tumor-induced osteomalacia. Calcif Tissue Int. 2021, 108:128-142. 10.1007\/s00223-020-00691-6","journal-title":"Calcif Tissue Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2025.07.015","article-title":"Diagnosis and management of hypophosphatemic disorders","volume":"31","author":"Liu ES","year":"2025","unstructured":"Liu ES. Diagnosis and management of hypophosphatemic disorders. Endocr Pract. 2025, 31:1592-1600. 10.1016\/j.eprac.2025.07.015","journal-title":"Endocr Pract"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1319","article-title":"Approach to the hypophosphatemic patient","volume":"97","author":"Imel EA","year":"2012","unstructured":"Imel EA, Econs MJ. Approach to the hypophosphatemic patient. J Clin Endocrinol Metab. 2012, 97:696-706. 10.1210\/jc.2011-1319","journal-title":"J Clin Endocrinol Metab"},{"key":"ref5","unstructured":"XLH treatment FDA approved. (2025). https.\/\/www.crysvita.com\/."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4233","article-title":"Burosumab for the treatment of tumor-induced osteomalacia","volume":"36","author":"Jan de Beur SM","year":"2021","unstructured":"Jan de Beur SM, Miller PD, Weber TJ, et al.. Burosumab for the treatment of tumor-induced osteomalacia. J Bone Miner Res. 2021, 36:627-635. 10.1002\/jbmr.4233","journal-title":"J Bone Miner Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-022-06516-6","article-title":"Long-term use of burosumab for the treatment of tumor-induced osteomalacia","volume":"34","author":"Crotti C","year":"2023","unstructured":"Crotti C, Zucchi F, Alfieri C, Caporali R, Varenna M. Long-term use of burosumab for the treatment of tumor-induced osteomalacia. Osteoporos Int. 2023, 34:201-206. 10.1007\/s00198-022-06516-6","journal-title":"Osteoporos Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-022-06432-9","article-title":"A literature review to understand the burden of disease in people living with tumour-induced osteomalacia","volume":"33","author":"Minisola S","year":"2022","unstructured":"Minisola S, Barlassina A, Vincent SA, Wood S, Williams A. A literature review to understand the burden of disease in people living with tumour-induced osteomalacia. Osteoporos Int. 2022, 33:1845-1857. 10.1007\/s00198-022-06432-9","journal-title":"Osteoporos Int"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis","volume":"19","author":"Shimada T","year":"2004","unstructured":"Shimada T, Hasegawa H, Yamazaki Y, et al.. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004, 19:429-435. 10.1359\/JBMR.0301264","journal-title":"J Bone Miner Res"},{"key":"ref10","unstructured":"Burosumab-twza (Crysvita) - medical clinical policy bulletins | Aetna. (2025). https.\/\/www.aetna.com\/cpb\/medical\/data\/900_999\/0932.html."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-025-01433-2","article-title":"Real-world effectiveness of burosumab in adults with X-linked hypophosphataemia (XLH) in the UK","volume":"116","author":"Bubbear J","year":"2025","unstructured":"Bubbear J, Lachmann R, Murphy E, et al.. Real-world effectiveness of burosumab in adults with X-linked hypophosphataemia (XLH) in the UK. Calcif Tissue Int. 2025, 116:122. 10.1007\/s00223-025-01433-2","journal-title":"Calcif Tissue Int"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/441135-treatment-of-fibroblast-growth-factor-23-mediated-renal-phosphate-wasting-with-burosumab-in-a-patient-with-chronic-kidney-disease-3b-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T23:39:50Z","timestamp":1766533190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/441135-treatment-of-fibroblast-growth-factor-23-mediated-renal-phosphate-wasting-with-burosumab-in-a-patient-with-chronic-kidney-disease-3b-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.99956","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,23]]}}}